Story perspectives

FDA Fast-Tracks Custom Gene Editing for Patients

11/1/2025

27 5

Summary

Story summary

The U.S. Food and Drug Administration (FDA) plans a faster approval process for custom gene-editing therapies.
Vinay Prasad, who oversees gene therapies, notes that advances like Crispr necessitate regulatory changes.
KJ Muldoon became the first patient to receive a custom gene edit, illustrating the shift.
Researchers are creating a new clinical trial framework to evaluate therapies for multiple genetic disorders, potentially reducing costs and time and increasing accessibility.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) plans a faster approval process for custom gene-editing therapies.
Vinay Prasad, who oversees gene therapies, notes that advances like Crispr necessitate regulatory changes.
KJ Muldoon became the first patient to receive a custom gene edit, illustrating the shift.
Researchers are creating a new clinical trial framework to evaluate therapies for multiple genetic disorders, potentially reducing costs and time and increasing accessibility.